Cargando…

Observational cohort study of rilpivirine (RPV) utilization in Europe

INTRODUCTION: Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce. METHODS: Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cozzi-Lepri, Alessandro, Peters, Lars, Pelchen-Matthews, Annegret, Neesgaard, Bastian, De Wit, Stephane, Johansen, Isik Somuncu, Edwards, Simon, Stephan, Christoph, Adamis, Georgios, Staub, Therese, Zagalo, Alexandra, Domingo, Pere, Elbirt, Daniel, Kusejko, Katharina, Brännström, Johanna, Paduta, Dzmitry, Trofimova, Tatyana, Szlavik, Janos, Zilmer, Kai, Losso, Marcello, Van Eygen, Veerle, Pai, Helen, Lundgren, Jens, Mocroft, Amanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357334/ https://www.ncbi.nlm.nih.gov/pubmed/35933352 http://dx.doi.org/10.1186/s12981-022-00457-0

Ejemplares similares

Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice
por: Melody, Kevin, et al.
Publicado: (2020)

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study
por: Rokx, Casper, et al.
Publicado: (2014)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)
por: Sinclair, Gary I, et al.
Publicado: (2023)

Rpv29, Rpv30 and Rpv31: Three Novel Genomic Loci Associated With Resistance to Plasmopara viticola in Vitis vinifera
por: Sargolzaei, Maryam, et al.
Publicado: (2020)

SUSY RPV Searches
por: Zhuang, Xuai
Publicado: (2017)

RPV Models Overview
por: Nangia, Saurabh
Publicado: (2022)

Grapevine Rpv3-, Rpv10- and Rpv12-mediated defense responses against Plasmopara viticola and the impact of their deployment on fungicide use in viticulture
por: Wingerter, Chantal, et al.
Publicado: (2021)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015
por: Laut, Kamilla, et al.
Publicado: (2018)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
por: Dandachi, Dima, et al.
Publicado: (2023)

RPV SUSY searches at ATLAS and CMS
por: Pettersson, Nora Emilia
Publicado: (2015)

Current status of RPV searches at ATLAS
por: Blocker, C
Publicado: (2013)

Two-omics data revealed commonalities and differences between Rpv12- and Rpv3-mediated resistance in grapevine
por: Chitarrini, Giulia, et al.
Publicado: (2020)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

Pathogen Adaptation to American (Rpv3-1) and Eurasian (Rpv29) Grapevine Loci Conferring Resistance to Downy Mildew
por: Marone Fassolo, Elena, et al.
Publicado: (2022)

1024. Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study
por: Garris, Cindy, et al.
Publicado: (2023)

Implementación de redes privadas virtuales (RPV) /
por: Brown, Steven
Publicado: (2001)

Search for mSUSY and RPV-SUSY at Tevatron
por: Nagy, E
Publicado: (2001)

Limit on the LSP mass in RPV SUSY scenario
por: Awunor, O
Publicado: (2001)

Searches for RPV SUSY in ATLAS, CMS and LHCb
por: Dyckes, Ian
Publicado: (2020)

Searches for RPV SUSY in ATLAS, CMS and LHCb
por: Karmakar, Saikat
Publicado: (2022)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Searches for RPV SUSY and long-lived particles at the LHC
por: Liu, Minghui
Publicado: (2015)

Study of RPV stop signals in paired dijet signatures
por: Venckauskaite, Monika
Publicado: (2016)

Search for RPV SUSY in the four-lepton final state
por: CMS Collaboration
Publicado: (2013)

Other Susy searches (RPV, GMSB...) and exotics at LEP
por: De Min, A
Publicado: (2001)

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1
por: Lombaard, Johan, et al.
Publicado: (2022)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Electron Microscopy Analysis of Viral Morphogenesis
por: Pelchen‐Matthews, Annegret, et al.
Publicado: (2007)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death
por: Casadellà, Maria, et al.
Publicado: (2017)

Search for RPV supersymmetry with three or more leptons and b-tags
por: CMS Collaboration
Publicado: (2012)

1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE)
por: Czarnogorski, Maggie, et al.
Publicado: (2020)

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study
por: Mills, Anthony, et al.
Publicado: (2020)

Biochemical mechanism of clinical resistance to rilpivirine
por: Singh, Kamalendra, et al.
Publicado: (2012)

The development of an effective synthetic route of rilpivirine
por: Zhang, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lkulrvhcb5ite4sg6h19985gcv